This study is for people with relapsed refractory multiple myeloma, a type of blood cancer. The goal is to see if the medicines elranatamab, carfilzomib, dexamethasone, and maplirpacept are safe and help treat this condition. The study has two parts:

Part 1 tests elranatamab with carfilzomib and dexamethasone. Part 2 tests elranatamab with maplirpacept. The medicines are given in 4-week cycles. Elranatamab is a shot under the skin, while others are given through a vein (IV). Participants in Part 1 also take dexamethasone as a pill or IV. This study lasts about 2 years, and researchers will check if these medicines work well together and are safe.

• Duration: About 2 years with regular visits.
• Treatment: All medicines given in cycles, some by shot and others by IV.
• Eligibility: Must have multiple myeloma and meet specific health criteria.